201 related articles for article (PubMed ID: 31015032)
1. Nanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: Multi-functionalization as an emerging strategy to optimize therapeutic efficacy.
Fang G; Zhang Q; Pang Y; Thu HE; Hussain Z
J Control Release; 2019 Jun; 303():181-208. PubMed ID: 31015032
[TBL] [Abstract][Full Text] [Related]
2. Multi-functionalization, a Promising Adaptation to Overcome Challenges to Clinical Translation of Nanomedicines as Nano-diagnostics and Nano-therapeutics for Breast Cancer.
Moti LAA; Hussain Z; Thu HE; Khan S; Sohail M; Sarfraz RM
Curr Pharm Des; 2021; 27(43):4356-4375. PubMed ID: 34459374
[TBL] [Abstract][Full Text] [Related]
3. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.
Hussain Z; Khan S; Imran M; Sohail M; Shah SWA; de Matas M
Drug Deliv Transl Res; 2019 Jun; 9(3):721-734. PubMed ID: 30895453
[TBL] [Abstract][Full Text] [Related]
4. Secreted Protein Acidic and Rich in Cysteine Mediated Biomimetic Delivery of Methotrexate by Albumin-Based Nanomedicines for Rheumatoid Arthritis Therapy.
Liu L; Hu F; Wang H; Wu X; Eltahan AS; Stanford S; Bottini N; Xiao H; Bottini M; Guo W; Liang XJ
ACS Nano; 2019 May; 13(5):5036-5048. PubMed ID: 30978282
[TBL] [Abstract][Full Text] [Related]
5. Liposome-Based Nanomedicine Therapeutics for Rheumatoid Arthritis.
Rahman M; Beg S; Anwar F; Kumar V; Ubale R; Addo RT; Ali R; Akhter S
Crit Rev Ther Drug Carrier Syst; 2017; 34(4):283-316. PubMed ID: 29199587
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicine for the Treatment of Rheumatoid Arthritis.
Jeong M; Park JH
Mol Pharm; 2021 Feb; 18(2):539-549. PubMed ID: 32502346
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.
Rubinstein I; Weinberg GL
Maturitas; 2012 Sep; 73(1):68-73. PubMed ID: 22264497
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.
Rubinstein I; Weinberg GL
Nanomedicine; 2012 Sep; 8 Suppl 1():S77-82. PubMed ID: 22640912
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicine - advantages for their use in rheumatoid arthritis theranostics.
Xiao S; Tang Y; Lv Z; Lin Y; Chen L
J Control Release; 2019 Dec; 316():302-316. PubMed ID: 31715278
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine is more than a supporting role in rheumatoid arthritis therapy.
Han Y; Huang S
J Control Release; 2023 Apr; 356():142-161. PubMed ID: 36863691
[TBL] [Abstract][Full Text] [Related]
11. Nanomedicines for the delivery of glucocorticoids and nucleic acids as potential alternatives in the treatment of rheumatoid arthritis.
Yu Z; Reynaud F; Lorscheider M; Tsapis N; Fattal E
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1630. PubMed ID: 32202079
[TBL] [Abstract][Full Text] [Related]
12. Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer.
Zhang J; Sun J; Li C; Qiao H; Hussain Z
J Nanobiotechnology; 2023 Mar; 21(1):106. PubMed ID: 36964547
[TBL] [Abstract][Full Text] [Related]
13. Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art.
Rahman M; Sharma G; Thakur K; Anwar F; Katare OP; Goni VG; Kumar V; Zamzami MA; Akhter S
Curr Top Med Chem; 2017; 17(2):162-173. PubMed ID: 28093980
[TBL] [Abstract][Full Text] [Related]
14. Move to Nano-Arthrology: Targeted Stimuli-Responsive Nanomedicines Combat Adaptive Treatment Tolerance (ATT) of Rheumatoid Arthritis.
Liu L; Guo W; Liang XJ
Biotechnol J; 2019 Jan; 14(1):e1800024. PubMed ID: 30221835
[TBL] [Abstract][Full Text] [Related]
15. Designing micro- and nano-particles for treating rheumatoid arthritis.
Mitragotri S; Yoo JW
Arch Pharm Res; 2011 Nov; 34(11):1887-97. PubMed ID: 22139688
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines targeting activated immune cells and effector cells for rheumatoid arthritis treatment.
Deng Y; Zheng H; Li B; Huang F; Qiu Y; Yang Y; Sheng W; Peng C; Tian X; Wang W; Yu H
J Control Release; 2024 Jul; 371():498-515. PubMed ID: 38849090
[TBL] [Abstract][Full Text] [Related]
17. Distribution of Podoplanin in Synovial Tissues in Rheumatoid Arthritis Patients Using Biologic or Conventional Disease-Modifying Anti-Rheumatic Drugs.
Takakubo Y; Oki H; Naganuma Y; Saski K; Sasaki A; Tamaki Y; Suran Y; Konta T; Takagi M
Curr Rheumatol Rev; 2017; 13(1):72-78. PubMed ID: 27030253
[TBL] [Abstract][Full Text] [Related]
18. Dextran sulfate nanoparticles as a theranostic nanomedicine for rheumatoid arthritis.
Heo R; You DG; Um W; Choi KY; Jeon S; Park JS; Choi Y; Kwon S; Kim K; Kwon IC; Jo DG; Kang YM; Park JH
Biomaterials; 2017 Jul; 131():15-26. PubMed ID: 28371624
[TBL] [Abstract][Full Text] [Related]
19. Targeted drug-delivery systems in the treatment of rheumatoid arthritis: recent advancement and clinical status.
Gorantla S; Singhvi G; Rapalli VK; Waghule T; Dubey SK; Saha RN
Ther Deliv; 2020 Apr; 11(4):269-284. PubMed ID: 32434463
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicine Strategies for Anti-Inflammatory Treatment of Noninfectious Arthritis.
Chen L; Wang Y; Sun L; Yan J; Mao HQ
Adv Healthc Mater; 2021 Jun; 10(11):e2001732. PubMed ID: 33870656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
